Test more accurately identifies four mutations for which FDA-approved drugs...
Test more accurately identifies four mutations for which FDA-approved drugs exist and offers faster turn-around time between initial testing and commencement of therapy

Source: M. D. Anderson Cancer Center

NSCLC

Liquid biopsy as effective as tissue biopsy for non-small cell lung cancer

Test more accurately identifies four mutations for which FDA-approved drugs exist and offers faster turn-around time between initial testing and commencement of therapy.

A multi-center study led by researchers at The University of Texas MD Anderson Cancer Center revealed that a liquid biopsy test called Guardant360®, is comparable to standard tissue biopsies in detection of guideline recommended biomarkers in advanced non-small cell lung cancer (NSCLC), has a faster turn-around time, and has the potential to support identification of more patients who can be treated with targeted therapy. The study findings are significant given that 30 percent of lung cancers can be treated successfully with molecular-targeted therapies, which often yield higher response rates than chemotherapy. 

The multi-institutional trial was led by Vassiliki Papadimitrakopoulou, M.D., professor of Thoracic/Head and Neck Medical Oncology. “When choosing therapy for patients with NSCLC, it is vital that we know which patients have gene mutations that often respond to molecular therapies. The response rates can be up to 30 percent higher than with chemotherapy or immunotherapy, said Papadimitrakopoulou, “In the past, our only option to test for mutations was to rely on tissue-biopsy-based testing, which can be invasive, have serious complications, is time-consuming and often not adequate to test for all relevant targetable mutations.”

Photo
Vassiliki Papadimitrakopoulou, M.D., professor of Thoracic/Head and Neck Medical Oncology.
Source: M. D. Anderson Cancer Center

In this comprehensive liquid biopsy study conducted at several participating institutions, Guardant360 employed cell-free tumor DNA (cfDNA) in blood to test for mutations in 282 patients. The test detected seven known predictive biomarkers including genomic alterations in ROS1, BRAF, RET, MET, ALK, EGFR and ERBB2, and one prognostic biomarker, KRAS mutations. Standard tissue sampling detected at least one of predictive biomarkers in 60 patients, while Guardant360 identified biomarkers in 77 patients. Among the remaining 193 patients who did not have one of the seven biomarkers, the liquid biopsy test found the KRAS mutation in 92 patients, compared to 24 patients with standard tissue sampling. 

Therapies specifically targeting EGFR, ALK, ROS1 and BRAF gene mutations or fusions are already approved by the U.S. Food and Drug Administration. “We know that guideline-recommended testing is normally completed in only 8 percent of patients with NSCLC,” said Papadimitrakopoulou. “This does not provide all the crucial information for physicians to make an informed therapy decision. This study shows that a highly sensitive and specific liquid biopsy should be part of the standard of care for these patients.” 

The study reported a median turn-around time from test order to final results of nine days for the liquid biopsy test, compared to 15 days for tissue-based testing. “Given that advanced NSCLC is often fatal, it is important we get patients on treatment at the earliest possible time,” said Papadimitrakopoulou. “Our findings show that we can greatly reduce the amount of time between testing and initiation of therapy.” 

Source: University of Texas M. D. Anderson Cancer Center

01.03.2019

Read all latest stories

Related articles

Photo

Personalized diagnostics

AI checks effectiveness of immunotherapy

Scientists from the Case Western Reserve University digital imaging lab use Artificial Intelligence (AI) to predict which lung-cancer patients will benefit from expensive immunotherapy. This is done…

Photo

Boosting our immune surveillance

Antibodies PD-1 and PD-L1: a quantum leap in cancer therapy

Immuno-oncology is a therapy in which the body’s immune system treats a tumour. Dr Eric Borges, from the Research and Development Centre at Boehringer Ingelheim Pharma GmbH in Germany, explains why…

Photo

Cancer management

The enormous potential of liquid biopsy

It is non-invasive, delivers a chance of early diagnosis, prognostic information and sequential monitoring, and, believes Professor Francesco Salvatore, the enormous potential of liquid biopsies has…

Related products

Streck – Cell-Free RNA BCT

Liquid biopsy

Streck – Cell-Free RNA BCT

Streck
Beckman Coulter – Access 25(OH) Vitamin D Total

Immunoassays

Beckman Coulter – Access 25(OH) Vitamin D Total

Beckman Coulter, Inc.
Beckman Coulter – Access Active B12

Immunoassays

Beckman Coulter – Access Active B12

Beckman Coulter, Inc.
Beckman Coulter – Access Procalcitonin (PCT)

Immunoassays

Beckman Coulter – Access Procalcitonin (PCT)

Beckman Coulter, Inc.